These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
141 related articles for article (PubMed ID: 16408858)
1. In vitro and in vivo evaluation of topical formulations of spantide II. Kikwai L; Babu RJ; Prado R; Kolot A; Armstrong CA; Ansel JC; Singh M AAPS PharmSciTech; 2005 Oct; 6(4):E565-72. PubMed ID: 16408858 [TBL] [Abstract][Full Text] [Related]
2. Percutaneous absorption and anti-inflammatory effect of a substance P receptor antagonist: spantide II. Babu RJ; Kikwai L; Jaiani LT; Kanikkannan N; Armstrong CA; Ansel JC; Singh M Pharm Res; 2004 Jan; 21(1):108-13. PubMed ID: 14984264 [TBL] [Abstract][Full Text] [Related]
3. Preformulation stability of Spantide II, a promising topical anti-inflammatory agent for the treatment of psoriasis and contact dermatitis. Kikwai L; Babu RJ; Kanikkannan N; Singh M J Pharm Pharmacol; 2004 Jan; 56(1):19-25. PubMed ID: 14979997 [TBL] [Abstract][Full Text] [Related]
4. Enhanced skin permeation using polyarginine modified nanostructured lipid carriers. Shah PP; Desai PR; Channer D; Singh M J Control Release; 2012 Aug; 161(3):735-45. PubMed ID: 22617521 [TBL] [Abstract][Full Text] [Related]
5. Development of ciclopirox olamine topical formulations: evaluation of drug release, penetration and cutaneous retention. Pinheiro VA; Serikaku D; Baby AR; Velasco MV; Kaneko TM; Consiglieri VO Pharm Dev Technol; 2015 Mar; 20(2):197-203. PubMed ID: 24286179 [TBL] [Abstract][Full Text] [Related]
6. Cutaneous allergic contact dermatitis responses are diminished in mice deficient in neurokinin 1 receptors and augmented by neurokinin 2 receptor blockage. Scholzen TE; Steinhoff M; Sindrilaru A; Schwarz A; Bunnett NW; Luger TA; Armstrong CA; Ansel JC FASEB J; 2004 Jun; 18(9):1007-9. PubMed ID: 15084523 [TBL] [Abstract][Full Text] [Related]
7. Skin permeating nanogel for the cutaneous co-delivery of two anti-inflammatory drugs. Shah PP; Desai PR; Patel AR; Singh MS Biomaterials; 2012 Feb; 33(5):1607-17. PubMed ID: 22118820 [TBL] [Abstract][Full Text] [Related]
8. Formulation and evaluation of curcumin gel for topical application. Patel NA; Patel NJ; Patel RP Pharm Dev Technol; 2009; 14(1):80-9. PubMed ID: 18821270 [TBL] [Abstract][Full Text] [Related]
9. Formulation and ex vivo evaluation of rofecoxib gel for topical application. Das MK; Ahmed AB Acta Pol Pharm; 2007; 64(5):461-7. PubMed ID: 18540168 [TBL] [Abstract][Full Text] [Related]
10. Effect of oleic acid modified polymeric bilayered nanoparticles on percutaneous delivery of spantide II and ketoprofen. Shah PP; Desai PR; Singh M J Control Release; 2012 Mar; 158(2):336-45. PubMed ID: 22134117 [TBL] [Abstract][Full Text] [Related]
11. Effect of penetration enhancers on the release and skin permeation of bupranolol from reservoir-type transdermal delivery systems. Babu RJ; Pandit JK Int J Pharm; 2005 Jan; 288(2):325-34. PubMed ID: 15620873 [TBL] [Abstract][Full Text] [Related]
12. Increased susceptibility of mice to Salmonella infection following in vivo treatment with the substance P antagonist, spantide II. Kincy-Cain T; Bost KL J Immunol; 1996 Jul; 157(1):255-64. PubMed ID: 8683123 [TBL] [Abstract][Full Text] [Related]
13. Topical drug delivery by a polymeric nanosphere gel: Formulation optimization and in vitro and in vivo skin distribution studies. Batheja P; Sheihet L; Kohn J; Singer AJ; Michniak-Kohn B J Control Release; 2011 Jan; 149(2):159-67. PubMed ID: 20950659 [TBL] [Abstract][Full Text] [Related]
14. Influence of cellulose derivative and ethylene glycol on optimization of lornoxicam transdermal formulation. Shahzad Y; Khan Q; Hussain T; Shah SN Int J Biol Macromol; 2013 Oct; 61():26-32. PubMed ID: 23827761 [TBL] [Abstract][Full Text] [Related]
16. Stability and degradation profiles of Spantide II in aqueous solutions. Kikwai L; Babu RJ; Kanikkannan N; Singh M Eur J Pharm Sci; 2006 Feb; 27(2-3):158-66. PubMed ID: 16266798 [TBL] [Abstract][Full Text] [Related]
17. Evaluation of in vivo efficacy of topical formulations containing soybean extract. Georgetti SR; Casagrande R; Verri WA; Lopez RF; Fonseca MJ Int J Pharm; 2008 Mar; 352(1-2):189-96. PubMed ID: 18079076 [TBL] [Abstract][Full Text] [Related]
18. Percutaneous delivery of α-melanocyte-stimulating hormone for the treatment of imiquimod-induced psoriasis. Shah PP; Desai PR; Boakye CH; Patlolla R; Kikwai LC; Babu RJ; Singh M J Drug Target; 2016; 24(6):537-47. PubMed ID: 26582563 [TBL] [Abstract][Full Text] [Related]
19. Fingolimod Hydrochloride Gel for Dermatological Applications: Optimization of Formulation Strength and Effect of Colloidal Oatmeal (Aveeno®) as Penetration Enhancer. Tamakuwala M; Stagni G AAPS PharmSciTech; 2016 Aug; 17(4):907-14. PubMed ID: 26729522 [TBL] [Abstract][Full Text] [Related]
20. Efficacy study of vesicular gel containing methotrexate and menthol combination on parakeratotic rat skin model. Nagle A; Goyal AK; Kesarla R; Murthy RR J Liposome Res; 2011 Jun; 21(2):134-40. PubMed ID: 20557280 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]